Privium Fund Management B.V. Acquires 41,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Privium Fund Management B.V. lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 52.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,000 shares of the company's stock after acquiring an additional 41,000 shares during the quarter. Privium Fund Management B.V.'s holdings in Recursion Pharmaceuticals were worth $804,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its stake in Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock valued at $84,815,000 after buying an additional 4,120,685 shares during the last quarter. FMR LLC increased its position in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after acquiring an additional 170,810 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after acquiring an additional 656,003 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Recursion Pharmaceuticals by 17.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock worth $15,372,000 after purchasing an additional 333,323 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Recursion Pharmaceuticals by 2.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company's stock valued at $14,108,000 after purchasing an additional 43,078 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently commented on RXRX shares. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, KeyCorp dropped their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $8.25.

Recursion Pharmaceuticals Stock Performance

RXRX traded up $0.20 on Friday, hitting $6.68. The company's stock had a trading volume of 17,924,603 shares, compared to its average volume of 10,527,241. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $12.36. The firm has a market cap of $2.69 billion, a P/E ratio of -4.37 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company's 50 day simple moving average is $7.47 and its 200-day simple moving average is $7.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same quarter last year, the firm posted ($0.42) earnings per share. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.